BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29208651)

  • 1. A 12.3-kb Duplication Within the
    Lehner S; Ekhlasi-Hundrieser M; Detering C; Allerkamp H; Pfarrer C; von Depka Prondzinski M
    G3 (Bethesda); 2018 Feb; 8(2):577-585. PubMed ID: 29208651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of von Willebrand factor mRNA from the lung of pigs with severe von Willebrand disease by using a human cDNA probe.
    Wu QY; Bahnak BR; Coulombel L; Kerbiriou-Nabias D; Drouet L; Piétu G; Meulien P; Pavirani A; Caen JP; Meyer D
    Blood; 1988 May; 71(5):1341-6. PubMed ID: 3258769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A common frameshift mutation in von Willebrand factor does not alter mRNA stability but interferes with normal propeptide processing.
    Mohlke KL; Nichols WC; Rehemtulla A; Kaufman RJ; Fagerström HM; Ritvanen KL; Kekomăki R; Ginsburg D
    Br J Haematol; 1996 Oct; 95(1):184-91. PubMed ID: 8857958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic mutations in von Willebrand disease identified by DHPLC and DNA sequence analysis.
    Kakela JK; Friedman KD; Haberichter SL; Buchholz NP; Christopherson PA; Kroner PA; Gill JC; Montgomery RR; Bellissimo DB
    Mol Genet Metab; 2006 Mar; 87(3):262-71. PubMed ID: 16321553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.
    Yadegari H; Driesen J; Pavlova A; Biswas A; Hertfelder HJ; Oldenburg J
    Thromb Haemost; 2012 Oct; 108(4):662-71. PubMed ID: 22871923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor.
    de Jong A; Dirven RJ; Oud JA; Tio D; van Vlijmen BJM; Eikenboom J
    J Thromb Haemost; 2018 Jul; 16(7):1357-1368. PubMed ID: 29734512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic heterogeneity of severe von Willebrand disease type III in the German population.
    Schneppenheim R; Krey S; Bergmann F; Bock D; Budde U; Lange M; Linde R; Mittler U; Meili E; Mertes G
    Hum Genet; 1994 Dec; 94(6):640-52. PubMed ID: 7989040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
    Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype-phenotype correlation in a cohort of Portuguese patients comprising the entire spectrum of VWD types: impact of NGS.
    Fidalgo T; Salvado R; Corrales I; Pinto SC; Borràs N; Oliveira A; Martinho P; Ferreira G; Almeida H; Oliveira C; Marques D; Gonçalves E; Diniz M; Antunes M; Tavares A; Caetano G; Kjöllerström P; Maia R; Sevivas TS; Vidal F; Ribeiro L
    Thromb Haemost; 2016 Jul; 116(1):17-31. PubMed ID: 26988807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I.
    Zhang ZP; Lindstedt M; Falk G; Blombäck M; Egberg N; Anvret M
    Am J Hum Genet; 1992 Oct; 51(4):850-8. PubMed ID: 1415226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsense mediated decay of VWF mRNA subsequent to c.7674-7675insC mutation in type3 VWD patients.
    Shahbazi S; Baniahmad F; Zakiani-Roudsari M; Raigani M; Mahdian R
    Blood Cells Mol Dis; 2012 Jun; 49(1):48-52. PubMed ID: 22503077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease.
    Gallinaro L; Sartorello F; Pontara E; Cattini MG; Bertomoro A; Bartoloni L; Pagnan A; Casonato A
    Thromb Haemost; 2006 Dec; 96(6):711-6. PubMed ID: 17139363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.
    Ginsburg D; Konkle BA; Gill JC; Montgomery RR; Bockenstedt PL; Johnson TA; Yang AY
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3723-7. PubMed ID: 2786201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis of von Willebrand disease.
    Mohlke KL; Nichols WC; Ginsburg D
    Int J Clin Lab Res; 1999; 29(1):1-7. PubMed ID: 10356656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.